| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5137d258248f7d51a126917b4cd77e97 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-01 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R1-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23C9-1203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2016-01-08^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5b1e1b9b68406a132bc7cd8a0db1f5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b2f12ba9ea305fd8195b6edc433a979 |
| publicationDate |
2018-12-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018353552-A1 |
| titleOfInvention |
Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
| abstract |
The disclosure is concerned with a novel human intestinal isolate capable of converting L-lysine into butyrate and/or of converting fructose-lysine into butyrate. The novel isolate can be used as a probiotic or supplement to promote production of butyrate in the GI tract, thereby preventing and/or treating conditions or diseases that benefit from the production of butyrate. Additionally, the isolate may prevent and/or treat conditions or diseases caused by an excess of pathogenic bacteria in the GI tract, mediated by L-lysine, or mediated by fructose-lysine or other advanced glycation end products. |
| priorityDate |
2015-01-09^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |